Neuro Bio Assets

ASSETS OVERVIEW

      1. Therapeutic for Alzheimer’s combatting T14
      A novel drug treatment that could stabilise cell loss by combatting the pivotal toxin T14. NBP-14 is the lead compound in the preclinical phase towards IND status and subsequent clinical testing in the near future. Neuro-Bio is also developing a pipeline that involves screening smaller, potentially more druggable variants.
        2. Biomarker for AD based on T14 in blood
        Neuro-Bio is developing a blood-based biomarker with diagnostic and prognostic potential using 3 different outsourced approaches: (a) conventional detection method with a monoclonal antibody; (b) a proprietorial system using a polyclonal system and (c) an antibody-free, innovative method using machine learning and an optics detection system.
          3. A first-in-class, non-transgenic animal model of AD
          Currently genetically modified, ‘transgenic’ mouse models do not replicate the fully authentic Alzheimer profile, as well as being time-consuming and costly to produce. Given the Neuro-Bio approach based on the putatively pivotal mechanism driving Alzheimer’s, it follows that intracerebral administration of T14 to normal rodents, should result in a complete pathological scenario including impaired memory loss and appearance of traditional brain markers.
            4. Combatting metastases by blocking T14
            If T14 drives cell development then it might also feature in cancer (Garcia-Ratés and Greenfield 2017), a condition characterised by inappropriate cellular spread. This idea is supported by the anti-metastatic action of NBP14 in vitro (Pepper et al., 2017). Neuro-Bio is thus developing NBP14 as a drug for metastasis treatment with external partners currently testing in vivo.
              5. Skin aging and skin disorders
              If neurodegeneration and cancer are aberrant activations of a basic developmental system, driven by T14, it follows that this molecule would be operating still in adulthood, in the skin, – which is continuously in a state of development with epidermal skin cells constantly being made and replaced. Neuro-Bio is developing several applications of the T14-NBP14 technology for skin aging and skin disorders with external partners.

          T: +44 (0)1235 420 085
          E: info@neuro-bio.com

          NBO logo

          © All Rights Reserved NeuroBio

          ArabicChinese (Simplified)EnglishRussian